• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Drug-Device Combinations

Beta Bionics stock rises on Q3 beats, raised full-year guidance, advances iLet offerings

October 28, 2025 By Sean Whooley

Beta Bionics Logo (1)

Beta Bionics (Nasdaq:BBNX) shares got a boost after hours today on third-quarter results that came in ahead of the consensus forecast. Shares of BBNX rose around 20% to $29 apiece in post-market trading today. The Irvine, California-based automated insulin delivery device maker reported losses of $14 million. That equals 33¢ per share on sales of […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Beta Bionics

Orchestra BioMed, Terumo terminate drug-eluting balloon distro deal in $30M agreement

October 28, 2025 By Sean Whooley

Orchestra BioMed Virtue sirolimus angioinfusion balloon (SAB)

Orchestra BioMed (Nasdaq:OBIO) announced today that it entered into a termination and right of first refusal agreement with Terumo. The agreement relates to the New Hope, Pennsylvania-based company’s Virtue Sirolimus AngioInfusion Balloon (SAB). It supersedes and terminates a prior distribution agreement between the companies and grants Terumo a right of first refusal (ROFR) to acquire […]

Filed Under: Business/Financial News, Cardiovascular, Drug-Device Combinations, Featured, Funding Roundup, Vascular Tagged With: orchestrabiomed, Terumo Corp.

ViCentra adds Dexcom, Medtronic Diabetes veterans to leadership team

October 28, 2025 By Sean Whooley

ViCentra Karen Baxter Jay Little headshots

ViCentra announced today that it appointed former Dexcom and Medtronic Diabetes leaders to new executive roles. The Dutch insulin pump maker continues to expand its senior leadership as it looks to advance its Kaleido patch pump system. It appointed Karen Baxter, former VP and GM at Dexcom, to the position of SVP of sales for […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Personnel, Technology Tagged With: Personnel Moves, ViCentra

Dexcom adds Stanford Medicine chair to its board of directors

October 27, 2025 By Sean Whooley

Euan Ashley Dexcom Board Stanford Medicine (1)

Dexcom (Nasdaq:DXCM) announced today that it appointed Dr. Euan Ashley to its board of directors, effective Oct. 24, 2025. Ashley, a renowned researcher, entrepreneur and clinician, brings extensive leadership experience across healthcare research institutions and private organizations. He currently serves as chair of the Dept. of Medicine at Stanford Health. Research areas for Ashley span […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Personnel, Technology Tagged With: Dexcom, Personnel Moves

Boston Scientific shares positive Agent drug-coated balloon findings

October 27, 2025 By Sean Whooley

Boston Scientific Agent drug-coated balloon DCB

Boston Scientific (NYSE: BSX) today shared findings from new analyses of its Agent drug-coated balloon (DCB). Agent serves as an alternative to traditional therapies like balloon angioplasty, additional layers of stenting or radiation. The paclitaxel-coated balloon transfers a therapeutic dose of drug to the vessel wall, helping to prevent in-stent restenosis (ISR) reoccurrence. The FDA […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Vascular Tagged With: Boston Scientific

Orchestra BioMed enrolls first patient in Sirolumus AngioInfusion balloon trial

October 27, 2025 By Sean Whooley

Orchestra BioMed Virtue sirolimus angioinfusion balloon (SAB)

Orchestra BioMed (Nasdaq:OBIO) today announced the first patient enrollments in a study of its Virtue Sirolimus AngioInfusion Balloon (SAB). The FDA investigational device exemption (IDE) trial compares the Virtue SAB to the Boston Scientific Agent paclitaxel-coated balloon. Agent is currently the only FDA-approved drug-coated balloon (DCB) for coronary indication, picking up approval in March. New Hope, […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Vascular Tagged With: orchestrabiomed

Vivani prices $15.7M offering

October 27, 2025 By Sean Whooley

Vivani NanoPortal diabetes implant

Vivani Medical (Nasdaq:VANI) announced that it priced a best efforts registered direct offering of 6 million shares of common stock. The Alameda, California-based company priced the shares at $1.62 apiece. It also announced a concurrent private placement of more than 3.7 million shares of common stock at the same price. Gregg Williams, the company’s board […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Funding Roundup, Implants, Technology Tagged With: Vivani Medical

Multiple studies back Cordis Selution SLR drug-eluting balloon

October 26, 2025 By Sean Whooley

Cordis Selution SLR drug-eluting balloon

Cordis today announced new findings from a duo of studies supporting the use of its Selution SLR drug-eluting balloon (DEB) system. Miami Lakes, Florida-based Cordis announced results from the SELUTION DeNovo and SELUTION 4ISR trials at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco. Both randomized clinical trials demonstrated positive outcomes that met […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Stents, Vascular Tagged With: cordis

Ypsomed launches YpsoLoop autoinjector platform designed for circularity

October 23, 2025 By Sean Whooley

Ypsomed YpsoLoop autoinjector (1)

Ypsomed announced that it launched YpsoLoop, its first autoinjector platform designed for circularity. The Swiss drug delivery device maker says the two new 1 mL and 2.25 mL platforms enable material recovery. Their design enables automated disassembly and efficient recycling while offering the convenience of a pre-filled, two-step autoinjector. Ypsomed said the YpsoLoop platform integrates […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Technology Tagged With: Ypsomed

Insulet adds JPMorgan veteran to its board of directors

October 23, 2025 By Sean Whooley

Robbie Huffines Insulet board (1)

Insulet (Nasdaq:PODD) announced today that it appointed Robert “Robbie” L. Huffines to its board of directors. Huffines, a former global chair of investment banking at JPMorgan Chase & Co., joins the automated insulin delivery technology maker’s board effective Oct. 31, 2025. He joins as an independent director and a member of the Insulet Audit Committee. […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Personnel, Technology Tagged With: Insulet, Personnel Moves

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 27
  • Page 28
  • Page 29
  • Page 30
  • Page 31
  • Interim pages omitted …
  • Page 374
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS